🧵Rialo: Layer 1 Blockchain Bringing Our Real World On-Chain 🌍
What if a blockchain didn't just map real world assets, but became a bridge so seamless you could interact with the real world without oracles or extra middleware ?
Meet RialoHQ, the public chain redefining what 'real-world' means 👇
@RialoHQ
🎨 MAME Creative Challenge.
MAME was born on BNB Chain.
This challenge is our way of celebrating the ecosystem where MAME began and the community that continues to build it.
✨️Theme: MAME on BNB Chain ✨️
Show us your vision of MAME on BNB Chain.
There are no limits to your creativity. Any medium, any style, any technique is welcome.
Illustrations, memes, pixel art, 3D, videos, comics, cosplay, handmade creations, or anything else you can imagine. Surprise us.
A great idea can be as powerful as great artwork. Creativity, originality, and heart matter more than perfect execution.
Be original. Entries must be your own work.
🏆 Prize Pool: $10,000
👑 50 winners: $200 each
📋 How to Join
• Follow @MameBNB
• Like & Retweet the announcement
• Share your creation on X
• Tag @MameBNB and @BNBCHAIN
• Use #MAMECreativeChallenge and #SaveMemeCulture
• Tag 3 friends and invite them to join
📅 Deadline:
3 August 2026 • 14:00 UTC
Winners will be announced within 72 hours after the submission deadline.
Become part of MAME history.
Save Meme Culture 🖤
Conclusions
Bio Protocol's Twitter presence today demonstrated exceptional execution of a complex dual token launch, with proactive community management and authentic positive sentiment. The combination of strong performance metrics (32x/10.5x gains), responsive technical support, and organic community enthusiasm positions Bio Protocol as a leading DeSci infrastructure platform with significant Twitter mindshare and engagement momentum.
✨🧵Bio Protocol Twitter Insights - Sep 23, 2025
TL;DR
@BioProtocol dominated Twitter today with successful TGE launches for @BiomeAI and eDMT tokens, achieving 32x and 10.5x gains respectively.
Community sentiment was overwhelmingly positive despite minor technical issues, with strong engagement around the launchpad's effectiveness and DeSci innovation momentum 👇
Community Response & Engagement Patterns
Sentiment Analysis
Community interactions were overwhelmingly positive with organic enthusiasm rather than coordinated hype. Key response themes included:
> DeSci Innovation: Users positioned Bio Protocol as a leader in decentralized science integrated with AI-driven biotech
> Performance Celebration: Excitement over rapid post-TGE gains validating the auction model and BioDAO integration
> Educational Sharing: Community members sharing contract addresses and app navigation tips
Engagement Metrics
> Official Announcements: Bio Protocol's TGE posts generated strong engagement with reply threads showing enthusiastic participation. The community response felt authentic, driven by genuine interest in the BiomeAI and eDMT mechanics rather than promotional noise.
> Warning Against 'Jeeters': Official posts emphasized penalties for early heavy selling (temporary XP restrictions), encouraging long-term holding behavior.
🎯 The Bottom Line: While retail fights over memecoins, institutional money is quietly flowing into DeSci. FatDAO sits at the intersection of three massive trends:
• Obesity epidemic solutions
• Decentralized science funding
• Community-owned biotech IP
The question isn't IF this space explodes, its which projects survive the clinical validation phase. 🧬
🚨 While everyone's obsessing over Ozempic's $150B market, there's a $4 TRILLION problem no one's talking about
▸ 2.2 billion people are overweight/obese globally, creating the largest economic burden in human history. But what if the solution isn't expensive injections, but your gut microbiome ? 🧵👇
@BioProtocol@FatDAO_
📊 Why This Could 100x:
✅ Largest addressable market in crypto ($4T global burden)
✅ Experienced team with real pharma background
✅ First-mover in metabolic health DeSci
✅ Bio Protocol ecosystem backing (11 BioDAOs total) ✅ Community airdrop for early product buyers coming soon
Timeline: Lab setup Q2 2025 → Clinical trials 2027 → Commercial launch 2028